Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

424P - Could total neoadjuvant therapy (TNT) become a new standard in locally advanced rectal cancer (LARC)? A systematic review and meta-analysis (MA) of TNT vs. standard chemoradiotherapy (CRT)

Date

17 Sep 2020

Session

E-Poster Display

Topics

Cytotoxic Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

Maria Carmen Riesco Martínez

Citation

Annals of Oncology (2020) 31 (suppl_4): S409-S461. 10.1016/annonc/annonc270

Authors

M.C. Riesco Martínez, C. Grávalos, P. Espinosa-Olarte, A. La Salvia, A. Modrego-Sánchez, L. Robles, R. Garcia-Carbonero

Author affiliations

  • Medical Oncology Department, Hospital Universitario 12 De Octubre, 28041 - Madrid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 424P

Background

Multimodality treatment has been the standard of care for LARC for the past decades, but the optimal sequencing strategy is a matter of debate. The addition of induction or consolidation chemotherapy (CT) to standard neoadjuvant CRT may increase tumour downstaging and anticipate systemic treatment of micrometastatic disease. However, several randomized clinical trials (RCT) have evaluated the role of TNT vs. CRT with inconsistent results, with the small size of most studies possibly leading to an underestimation of the effect of the TNT strategy. We therefore performed a systematic review and MA of RCTs in this setting to synthesize available data and help decision-making.

Methods

A systematic search was performed through MEDLINE, EMBASE, ESMO and ASCO meeting abstracts up to May 2020 to identify RCTs for neoadjuvant treatment comparing standard neoadjuvant radiotherapy vs. TNT (induction or consolidation CT + RT) followed by surgery. Studies were reviewed by two authors and discrepancies were resolved by consensus or by a third author. Data including pathological complete response (pCR) rate, disease-free survival (DFS), overall survival (OS) and adverse effects (AEs) were extracted. The primary endpoint was the pCR rate. A MA with fixed and random effect models comparing the different regimens with direct comparisons was conducted.

Results

Eight RCTs including 2175 patients with stage II-III LARC were identified. Overall, the pooled analysis demonstrated that TNT significantly improved pCR rate (OR= 0.52, 95% CI 0.38-0.71, p < 0.001) and 3 year-DFS (HR=0.73, 95% CI 0.62-0.87, p=0.01). No difference was found in 3 year-OS among treatment strategies (HR=0.89, 95% CI 0.71-1.10). When Short Course RT and CRT trials were analysed separately, a statistically significant benefit in pCR ( HR=0.51,p=0.003; HR 0.7, P=0.02 respectively) and 3 y-DFS rates (HR= 0.75, p=0.003;HR=0.82, P=0.03) was maintained, favouring the TNT strategy. Grade 3-4 AEs were not significantly different in both strategies (OR=1.1; P=0.33). No significant heterogeneity was found among RCTs.

Conclusions

The results of direct MA suggest that TNT vs. CRT improves pCR and 3-y DFS rates for patients with LARC. TNT may become a new standard of care in LARC, although longer follow-up is needed to properly assess its impact on OS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

M.C. Riesco Martínez: Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy: Novartis; Advisory/Consultancy: Bayer; Travel/Accommodation/Expenses: Servier. C. Grávalos: Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Sanofi; Advisory/Consultancy, Speaker Bureau/Expert testimony: Merck; Advisory/Consultancy: Bayer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Servier; Advisory/Consultancy, Speaker Bureau/Expert testimony: Amgen; Travel/Accommodation/Expenses: Pierre-Fabre. P. Espinosa-Olarte: Travel/Accommodation/Expenses: Ipsen; Travel/Accommodation/Expenses: Novartis; Travel/Accommodation/Expenses: Pfizer. A. Modrego-Sánchez: Travel/Accommodation/Expenses: Novartis. R. Garcia-Carbonero: Advisory/Consultancy, Speaker Bureau/Expert testimony: AAA; Advisory/Consultancy, Speaker Bureau/Expert testimony: Bayer; Speaker Bureau/Expert testimony: MSD; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Ipsen; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pierre Fabre; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Servier; Speaker Bureau/Expert testimony: Sanofi; Advisory/Consultancy, Speaker Bureau/Expert testimony: Merck. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.